CELUW Celularity Inc
CELUW has been delisted. The issuer filed Form 25-NSE with the SEC on 2026-07-22, and our last price is from 2026-07-17. Price, chart and technicals are therefore not shown. Company filings and reported financials below remain available.
Updated
Healthcare · Pharmaceutical Preparations
Celularity Inc (CELUW) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $54 million. Price data for CELUW is unavailable — our feed has carried no quote since 2026-07-17. Revenue declined 51.0% year over year.
Chart hidden: no price data for CELUW since 2026-07-17. Company filings and financials below are current.
Financials
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| FY 2025 | $-3.59 | 2026-04-30 |
| Q3 2025 | $-2.74 | 2025-11-14 |
| Q2 2025 | $-1.86 | 2025-08-29 |
| Q1 2025 | $-0.84 | 2025-08-29 |
| FY 2025 | $-2.64 | 2026-04-30 |
| Q3 2025 | $-2.05 | 2025-11-14 |
Pharmaceutical Preparations peers
CELUW vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.